Approval · Notice of Compliance 14746 · 2013
TRELSTAR: Notice of Compliance 14746
Issued September 11, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14746
- Date
- September 11, 2013
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To support a new formulation of trelstar (triptorelin pamoate for injectable suspension) designed to release 22.5 mg of the active moiety over a period of 168 days (6 month sloww release) for use in the palliative treatment of advanced prostate cancer
- Therapeutic class
- Luteinizing hormone-releasing hormone (lhrh) analogue
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRELSTAR | 02412322 | Marketed |
Medicinal ingredients
- TRIPTORELIN PAMOATE 22.5 MG per VIAL